Fortress Biotech

197 articles with Fortress Biotech

• Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex

  8/11/2022

  Fortress Biotech, Inc. today announced that Triplex, a cytomegalovirus (“CMV”) vaccine being developed by its subsidiary Helocyte, Inc. (“Helocyte”), received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (“NIAID/NIH”) that could provide over $20 million in non-dilutive funding.

• Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

  8/11/2022

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.

• Fortress Biotech Appoints David Jin as Chief Financial Officer

  7/22/2022

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the appointment of David Jin as Chief Financial Officer effective August 16, 2022.

• Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

  5/31/2022

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that its subsidiary company, UR-1 Therapeutics, Inc. (“UR-1”), dosed the first patient in a Phase 1 clinical trial evaluating Dotinurad for the treatment of gout in the United States.

• Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences

  5/18/2022

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in May 2022.

• Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

  5/12/2022

  Fortress Biotech, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.

• Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/7/2022

  Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 1:30 p.m.

• Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

  4/1/2022

  Fortress Biotech, Inc. today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline.

• Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights

  3/28/2022

  Fortress Biotech, Inc. today announced financial results and recent corporate highlights for the full-year ended December 31, 2021.

• Fortress Biotech to Participate in Three March 2022 Investor Conferences

  3/9/2022

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022.

• Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

  3/3/2022

  Fortress Biotech, Inc. today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline.

• Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference

  2/7/2022

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference on Wednesday, February 9, 2022, at 9:30 a.m. ET and will participate in one-on-one meetings during the conference.

• Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference

  1/6/2022

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the H.C. Wainwright BioConnect Virtual Conference scheduled to take place from Monday, January 10 through Thursday, January 13, 2022.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

  12/16/2021

  Fortress Biotech, Inc. and its partner company, Helocyte, Inc., (“Helocyte”) today announced that a Phase 2 double-blind, randomized, placebo-controlled clinical trial has been initiated to evaluate the safety and efficacy of Triplex, a cytomegalovirus (“CMV”) vaccine, in eliciting a CMV-specific immune response and reducing CMV replication in people living with HIV.

• Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

  11/15/2021

  Fortress Biotech, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.

• Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference

  10/18/2021

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at Dawson James Securities’ 6th Annual Small Cap Growth Conference.

• Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

  9/29/2021

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), and a company it founded, Caelum Biosciences, Inc. (“Caelum”), today announced that AstraZeneca’s Alexion notified Caelum that it has exercised its option to acquire Caelum.

• Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference

  9/28/2021

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the Benzinga Healthcare Small Cap Conference, scheduled to take place from September 29-30, 2021.

• Fortress Biotech to Participate in Three September 2021 Investor Conferences

  9/9/2021

  Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2021.